Related by context. All words. (Click for frequent words.) 68 complete cytogenetic response 67 pCR 67 mg BID dose 66 ACR# responses 66 morphometric vertebral fractures 66 relapsed MM 66 HBeAg seroconversion 66 nondiabetic patients 66 #mg BID [001] 66 HER2 expression 66 hyperphenylalaninemia HPA due 66 lymphocytosis 65 #mg dose [002] 65 8mg/kg 65 biochemical relapse 65 mg kg dose 65 glycated hemoglobin levels 65 aminotransferase ALT 65 achieved CCyR 65 serum urate levels 65 Tumor shrinkage 65 RECORD1 64 paclitaxel cisplatin 64 advanced adenoma 64 Fasting blood glucose 64 Pharmacokinetic parameters 64 serum phosphate 64 mcg QD 64 ALT elevation 64 underwent surgical resection 64 PRADAXA #mg 64 aplastic anemia AA 64 Folfox 64 mcg BID 64 QTcF 64 MGd 64 TIMP 1 64 NMIBC 64 infliximab monotherapy 64 lumbar spine BMD 64 definite stent thrombosis 63 complete cytogenetic 63 CR nPR 63 specific antigen PSA 63 oxycodone CR 63 elevated ALT 63 lactate dehydrogenase LDH 63 PASI scores 63 HBeAg negative patients 63 Solid Tumors criteria 63 achieved ACR# 63 HGPIN 63 serum estradiol 63 receiving INTRON 63 N telopeptide 63 response CCyR 63 mg TID 63 SUVmax 63 recurrent VTE 63 #.#/#.# mmHg [001] 63 plus dexamethasone 63 locoregional recurrence 63 RECIST Response Evaluation Criteria 62 REMICADE monotherapy 62 SGPT 62 alanine aminotransferase 62 REYATAZ r arm 62 bone marrow reticulin deposition 62 placebo dexamethasone 62 CIMZIA TM 62 perioperatively 62 serum urate 62 mU liter 62 renal cell carcinomas 62 clodronate 62 papillary renal cell carcinoma 62 hypophosphatemia 62 postintervention 62 postoperative mortality 62 MAGE A3 ASCI 62 dexamethasone Decadron 62 seropositivity 62 clinicopathological features 62 elevated transaminases 62 mL/min/#.# m 2 62 detectable HCV RNA 62 Endometrial 62 advanced adenomas 62 tipranavir r 62 ELACYT 62 mcg albinterferon alfa 2b 62 K ras mutations 62 underwent resection 62 octreotide LAR 62 Arch Intern Med 62 prednisone prednisolone plus 62 TIMP 62 annualized relapse 61 fluvastatin 61 lopinavir r arm 61 aspartate aminotransferase 61 CYP#A# CYP#D# 61 reduce serum phosphate 61 serum uric acid 61 deep venous thromboses 61 p = NS 61 doxorubicin cyclophosphamide 61 stage IIIb IV 61 interleukin IL -6 61 chemoradiation therapy 61 HBeAg 61 whose tumors overexpress 61 comparator arm 61 Operative mortality 61 undetectable HBV DNA 61 T1 weighted images 61 KRAS mutations 61 BRAF V#E mutation 61 TAXUS p value 61 PSADT 61 DAS# CRP 61 Acetate Rectal Suppositories 61 ALT normalization 61 EpCAM expression 61 FUSILEV enhances 61 mg/m2 dose 61 binary restenosis 61 #.#ng/ml 61 p# biomarker 61 log# copies mL 61 CCyR 61 protein excretion 61 severe neutropenia 61 lumbar spine bone 61 hormone receptor negative 61 pT2 61 BRAF gene mutations 61 PREZISTA r arm 61 serum testosterone 61 glomerular filtration 61 IFN beta 60 colorectal carcinoma 60 mg kg Hematide 60 aminotransferases 60 aspartate aminotransferase AST 60 serum phosphorous 60 unresectable tumors 60 serum clusterin levels 60 experienced virologic failure 60 EXJADE 60 HBV infections 60 CC genotype 60 cytologically confirmed 60 moderate renal impairment 60 mg qd 60 idiopathic membranous nephropathy 60 mCi kg 60 mCi 60 candesartan cilexetil 60 MCyR 60 KRAS mutations occur 60 Response Evaluation Criteria 60 Ribavirin causes 60 -#.# log# 60 XIENCE V PROMUS Stent 60 % CI #.#-#.# [003] 60 MADRS score 60 Plasma concentrations 60 statin monotherapy 60 -#.# mg dL [002] 60 adjunctive placebo 60 ACR# response 60 KRAS wild 60 fosamprenavir 60 cTnI 60 sustained virological response 60 PLX STROKE targeting 60 baseline HbA1c 60 TTR gene 60 Nephrol Dial Transplant 60 FOLFOX6 60 hip BMD 60 B7 H3 60 hematologic toxicity 60 CIN2 + 60 lipoprotein Lp 60 log# reduction 60 serum calcium levels 60 paricalcitol 60 cyclophosphamide methotrexate 60 Stent thrombosis 60 anaphylactic reactions bronchospasm 60 GnRH agonist 60 pT3 60 paraprotein 60 lactate dehydrogenase 60 CYT# potent vascular disrupting 60 intact parathyroid hormone 60 -#.# log# copies mL 60 surgically resected 60 #.#mg/dL 60 -#.# mg dL [001] 60 Peg IFN 60 baseline FEV 60 resistant hormone refractory 60 biopsied breast 60 FOLFOX4 alone 60 urinary N telopeptide 60 nadolol 60 serum aminotransferase levels 60 Cystatin C 60 ptau 60 adjuvant tamoxifen 59 irinotecan doxorubicin oxaliplatin paclitaxel 59 eosinophil count 59 Ki# 59 Ishak fibrosis score 59 subcutaneous enoxaparin 59 Ann Oncol 59 serum cortisol 59 cytogenetic response 59 ischemia driven 59 Univariate analysis 59 5-fluorouracil/leucovorin 59 invasive carcinomas 59 metastatic malignant 59 corticosteroid dose 59 Platelet counts 59 antiangiogenic activity 59 elevated serum creatinine 59 novel VDA molecule 59 untreated metastatic melanoma 59 #mg BID [003] 59 dacarbazine DTIC 59 Mg Usa 59 ventricular tachyarrhythmia 59 heFH 59 serum prostate 59 calculated creatinine clearance 59 abacavir lamivudine 59 μg L 59 urate lowering therapy 59 anemia hemoglobin 59 Am J Cardiol 59 hours postdose 59 HER2 overexpression 59 % Confidence Interval 59 Flu Cy 59 cEVR 59 pancreatic prostate 59 HER2 amplified 59 naïve HCV 59 sUA 59 visceral metastases 59 ertapenem 59 ABSORB trial 59 preintervention 59 Thal Dex 59 Clin Chem 59 CLA supplementation 59 angiographic outcomes 59 achieving PASI 59 FDG uptake 59 Non inferiority 59 ng dL 59 PROCTOCORT ® Suppository Hydrocortisone 59 hypoperfusion 59 nodular partial response 59 EDEMA3 trial 59 medically inoperable 59 serum IGF 59 tirofiban 59 hematological parameters 59 ductal carcinomas 59 DAS# remission 59 Clusterin 59 NHANES III 59 prednisone prednisolone 59 Vidaza ® 59 lymph node metastasis 59 troponin T 59 carcinoembryonic antigen 59 serum phosphate levels 59 CVD mortality 59 dosing cohort 59 β blockers 59 aminotransferase levels 59 serum PSA 59 Index CDAI 59 peripheral blood mononuclear 59 glucuronide 59 hsCRP levels 59 % AST SGOT 59 quetiapine risperidone 59 trastuzumab Herceptin R 59 glycosylated hemoglobin HbA1c 59 fasting triglycerides 59 Natalizumab 59 β blocker 59 metastatic renal cell 58 tumors GIST 58 isoprostane 58 nonmetastatic 58 nodal metastases 58 3mg/kg 58 trimethoprim sulfamethoxazole 58 AVODART 58 GSTP1 58 blood phenylalanine Phe 58 HAM D# scores 58 fasting plasma glucose FPG 58 HIV RNA 58 primary patency 58 cardiac troponin T 58 RRM1 58 colorectal adenoma 58 riociguat 58 NLX P# 58 TP# mutations 58 prostate carcinoma 58 PSA nadir 58 thyrotropin 58 perioperative mortality 58 alkaline phosphatase ALP 58 atheroma volume 58 microvessel density 58 inhibin B 58 EDSS score 58 mIU ml 58 #mg doses [002] 58 galiximab 58 Preclinical Study 58 TRAIL R1 58 Nebulized 58 salmeterol fluticasone 58 alanine aminotransferase ALT 58 Ep CAM 58 nadroparin 58 #Gy 58 atazanavir ritonavir 58 affective psychosis 58 weekly CSBMs 58 timepoint 58 leukocytosis 58 Relapsed Refractory Multiple Myeloma 58 μmol L 58 #mg #mg #mg [003] 58 platelet reactivity 58 cisplatin gemcitabine 58 pmol L 58 EUS FNA 58 Ann Intern Med 58 postprocedure 58 gastric adenocarcinoma 58 myocardial necrosis 58 hemodynamically significant 58 perfusion defects 58 pancreatic carcinoma 58 timepoints 58 thyroglobulin 58 HPV-#/# 58 baseline Hb 58 diabetic rats 58 SVR# 58 Randomized Phase II 58 allogeneic HSCT 58 nmol liter 58 Adenomas 58 Phase 2b Clinical Trial 58 Lupuzor ™ 58 g trans fats 58 pharmacodynamic effects 58 hemoglobin A1c HbA1c 58 intravenous bisphosphonates 58 % CI #.#-#.# [007] 58 #F FDG PET 58 refractory chronic lymphocytic 58 AGTR1 58 #mg/day [001] 58 ovarian carcinoma 58 Lp PLA 2 58 circulating EPCs 58 undetectable viral 58 antibody titer 58 nephrotoxicity 58 Recombinant EPO 58 undetectable HCV RNA 58 univariate analysis 58 IGF binding 58 ULORIC 58 distant metastasis 58 glycated hemoglobin HbA1c 58 SLNB 58 mg/m2/day 58 mcg kg min 58 colorectal adenocarcinoma 58 hepatorenal syndrome 58 immunoblotting 58 Pischon 58 orchiectomy 58 unfractionated heparin UFH 58 serum insulin 58 perineural invasion 58 hemoglobin Hb 58 steroid dexamethasone 58 plasma cortisol 58 generalized edema 58 lung esophageal 58 transaminases 58 ALT flares 58 Suppository Hydrocortisone Acetate Rectal 58 baseline LDH 58 5-FU/LV 58 8 OHdG 58 abnormal p# 58 intravenous bolus 58 titrated glipizide 58 BRCA2 mutation carriers 58 Papillary 58 log# IU mL 58 CIN3 58 intima media thickness 58 oral allopurinol 58 achieved sustained virological 58 malondialdehyde MDA 58 aminotransferase elevations greater 58 receiving VICTRELIS 58 atypical hyperplasia 58 5 FU leucovorin 57 serum antibody 57 human chorionic gonadotropin hCG 57 Severity MSCS score 57 arterial thromboembolic events 57 fraction LVEF 57 liver histology 57 baseline serum creatinine 57 cytokeratin 57 immunohistochemical staining 57 4mg/kg 57 PEG IFN 57 Mg Uk 57 FSH CTP 57 IU ml 57 mycophenolate mofetil 57 agonistic human 57 partial remissions 57 HOMA IR 57 piperacillin tazobactam 57 dose clopidogrel 57 microalbumin test 57 dehydroepiandrosterone sulfate 57 neutrophil counts 57 BRAF mutations 57 conjunctival hyperemia 57 reinfarction 57 Hycamtin ® 57 coronary stenosis 57 Telik logo TELINTRA 57 severe exacerbations 57 plus aztreonam 57 FLT3 ITD 57 monocyte chemotactic protein 57 rFSH 57 ACR Pedi 57 interleukin IL -# 57 plasma HCV RNA 57 #rd Annual CTRC 57 Hypotension 57 iPTH 57 Atypical Hemolytic Uremic Syndrome 57 ADPKD 57 leucopenia 57 endoscopic remission 57 PROSTVAC VF 57 Febrile neutropenia 57 Postoperative complications 57 receiving prophylactic anticoagulation 57 postoperative morbidity 57 UACR 57 thromboembolic 57 fatigue asthenia 57 #mmHg [001] 57 antiretroviral naïve 57 liver metastasis 57 Crohn Disease Activity 57 thyrotropin levels 57 5 Fluorouracil 57 fetuin 57 flutamide 57 • dcastell@visalia.gannett.com • 57 permanently discontinue Vectibix 57 Proteinuria 57 EGFR TKI 57 Hazard Ratio HR 57 Combination REOLYSIN R 57 atypical ductal hyperplasia 57 pmol liter 57 IFN α 57 lispro 57 biochemical recurrence 57 situ LCIS 57 serum creatinine levels 57 enzyme elevations 57 sustained virologic response 57 HepG2 cells 57 monocyte chemoattractant protein 57 mg eq 57 atorvastatin #mg 57 eosinophilia 57 CRESTOR #mg 57 invasive ductal 57 HER2 positivity 57 NPH insulin 57 creatinine ratio 57 low dose Iluvien 57 familial aggregation 57 budesonide pMDI 57 epoetin alpha 57 breast carcinomas 57 mg m² 57 #ng/ml 57 TEAEs 57 recurrent venous thromboembolism 57 pretreatment serum 57 #:#-# [031] 57 gadolinium enhancing lesions 57 foveal thickness 57 postoperative complication 57 T#I [002] 57 Cancer Res 57 nonfatal MI 57 asymptomatic carotid stenosis 57 perioperative complications 57 endometrial hyperplasia 57 revascularizations 57 Patients Receiving 57 balsalazide 57 brand ciclesonide HFA 57 serum triglyceride levels 57 umol L 57 cytogenic 57 ovarian endometrial 57 Antigen Specific 57 posttransplant 57 SGOT 57 posttreatment 57 ropivacaine 57 esophageal carcinoma 57 #:#-# [029] 57 ATACAND 57 upper gastrointestinal bleeding 57 plus GP IIb 57 extracapsular extension 57 beta blocker therapy 57 Eur J Endocrinol 57 Score TOS 57 MLL2 57 leukocyte count 57 invasive lobular carcinoma 57 haematologic 57 Prostate specific antigen 57 GVAX Immunotherapy 56 Hb A1C 56 Relapsing Remitting Multiple Sclerosis 56 thyroid carcinoma 56 #.#mg/kg [002] 56 ARB telmisartan 56 Cathepsin B 56 serum potassium 56 infarct size 56 Levels Linked 56 syngeneic 56 cells uL 56 NNRTI resistance 56 virologic response 56 IV bisphosphonates 56 CrCl 56 progesterone receptor negative 56 heterozygotes 56 Available Seat Kilometres ASKs 56 achieved mucosal healing 56 Cream USP 1 56 adjunctive ABILIFY 56 highest tertile 56 QTc prolongation 56 lobular carcinoma 56 periprocedural 56 noncarriers 56 certolizumab 56 antibody titers 56 lamivudine monotherapy 56 Immunohistochemical staining 56 uM 56 IgG antibody 56 sitosterol 56 Pharmacokinetic 56 darbepoetin alpha 56 pg ml 56 subclinical hypothyroidism 56 microbiological eradication 56 nausea dehydration dyspnea 56 Median PFS 56 recurrent UTI 56 mRNA expression 56 serum HBV DNA 56 pretransplant 56 Prednisone Against Refractory 56 ErbB2 positive 56 1mg dose 56 LDH lactate dehydrogenase 56 mg hydrochlorothiazide 56 antigen PSA levels 56 statistical significance p 56 P = .# 56 NAbs 56 confidence interval #.#-#.# 56 lymphocyte counts 56 #OHD levels 56 HbA 1c levels 56 urinary calcium excretion 56 plasma pharmacokinetics 56 â ‰ ¥ 56 fibrin deposition 56 invasive lobular 56 adenoma 56 corrected QT interval 56 systolic dysfunction 56 J Am Coll 56 thromboembolic complications 56 EDSS scores 56 LHRH receptor positive 56 rs# [004] 56 mEq L 56 operable breast cancer 56 adjuvant cisplatin 56 Cancer Epidemiol Biomarkers Prev 56 Subgroup analyzes 56 p = .# [002] 56 radioiodine therapy 56 metabolic alkalosis 56 hepatic resection 56 N Engl J 56 neutrophil count 56 mg/# h 56 serum BDNF 56 antitumor effect 56 confirmed CCyR 56 Inhibin B 56 AST ALT 56 urine NGAL 56 Severe acneform rash 56 alanine transaminase 56 nodal metastasis 56 completely resected 56 prolactin levels 56 culture supernatants 56 undergone radical prostatectomy 56 transaminase elevations 56 aminotransferase 56 fasting glucose levels 56 Skin sterol 56 serum concentrations 56 carotid artery thickness 56 Relapsed Refractory 56 leukopenia 56 HIV HCV coinfected 56 polyp recurrence 56 MAGE A3 56 Index CDAI score 56 cardiac toxicity 56 fasting insulin 56 Postoperatively 56 HSCT 56 Leukemias 56 Soriatane R acitretin capsules 56 ASH Abstract # 56 calcium excretion 56 graft occlusion 56 kidney allograft 56 chlorambucil 56 adefovir treated 56 NSABP B 56 #.#g/day 56 urine albumin 56 echocardiographic parameters 56 HDRS 56 heparanase 56 macroalbuminuria 56 demonstrated antitumor activity 56 plasma triglycerides 56 triiodothyronine 56 cGy 56 microg 56 postdose 56 micrometastasis 56 lymphovascular invasion 56 KRAS status 56 creatinine levels 56 microalbuminuria 56 μg kg 56 urinary oxalate 56 preoperative PSA 56 trough FEV1 56 serum homocysteine 56 Eur Respir J 56 Ejection Fraction 56 neuropathy sensory 56 serum calcium 56 elevated CRP 56 Insulin sensitivity 56 grade cervical intraepithelial 56 serum sodium levels 56 BRCA1 mutation carriers 56 HER2 HER2 56 hepatectomy 56 cytoreductive surgery 56 ipsilateral stroke 56 μmol l 56 XL# administered orally 56 MACCE 56 adjuvant radiation 56 kBq kg 56 Hemodialysis Patients 55 artery stenosis 55 bFGF 55 serum lipid levels 55 serum selenium 55 Biopsies 55 LH FSH 55 HBV DNA levels 55 breast carcinoma 55 atrioventricular block 55 ug dose 55 eplerenone 55 nmol 55 ug kg 55 carotid stenosis 55 recurrent metastatic 55 immunoreactivity 55 cisplatin resistant 55 mIU L 55 hemagglutination inhibition HAI 55 urine cytology 55 PENNVAX ™ B 55 antigen PSA 55 euthyroid 55 ischemic lesions 55 creatine kinase 55 mmHg diastolic 55 transaminase 55 hepatocellular carcinomas 55 ABCB1 55 mg p = 55 tolterodine ER 55 urinary excretion 55 tumor histology 55 CK # plasma concentrations 55 bezafibrate 55 #.#/#.# mm Hg [003] 55 ipsilateral breast 55 progression TTP 55 viral titers 55 pulmonary exacerbations 55 IL#B 55 #q# deletion syndrome 55 urinary calcium 55 H. pylori eradication 55 T2 lesion volume 55 transferrin saturation 55 % CI #.#-#.# [001] 55 BRAF V#E 55 hamartomas 55 rectal tenesmus 55 pooled comparator 55 pancreatic adenocarcinoma 55 Thalomid ® 55 Solazed 55 Cmax 55 tapentadol ER 55 Histological analysis 55 sUA levels 55 anemia thrombocytopenia 55 plus glycoprotein IIb 55 stomatitis pharyngitis 55 carotid IMT 55 femoral neck BMD 55 prolonged QT interval 55 blood urea nitrogen 55 ERalpha 55 virologic failure 55 mL/min/#.# m2 55 rs# [001] 55 immunohistochemical 55 glutamic acid decarboxylase 55 confidence intervals CIs 55 baseline neutrophil counts 55 IOP lowering 55 mL sec 55 PCWP 55 postmenopausal osteoporotic women 55 mg BID 55 metastatic pancreatic 55 median CD4 55 XL# inhibits 55 HIV coinfected 55 hematological cancers notably 55 placebo p = 55 IgA deficiency 55 substantially excreted 55 serum vitamin D 55 epithelial tumors 55 bladder carcinoma 55 luteinising hormone LH 55 leiomyomas 55 NNT = 55 WEEK ENDING INDEX 55 CMV infection 55 Immunohistochemistry 55 Serum creatinine 55 elevated creatinine 55 lopinavir r 55 histologic subtype 55 nonfasting triglycerides 55 μg ml 55 Azacitidine 55 Renal Cell Carcinoma 55 baseline PASI 55 6MWD 55 rizatriptan 55 Kidney Int 55 NGAL 55 immunostaining 55 Histologic 55 histopathologic examination 55 bovine thrombin 55 lung ovary 55 serum albumin 55 dose dabigatran 55 bladder ovarian 55 univariate 55 non mutated KRAS 55 insulin degludec 55 doxazosin 55 UGT#A# * 55 Ph + acute lymphoblastic 55 histological subtype 55 X ULN 55 cardiac troponin 55 BENICAR 55 Kaplan Meier estimates 55 rhTSH 55 hematopoietic cancers 55 Renal Cell Carcinoma RCC 55 Hurthle cell 55 glycosylated hemoglobin 55 obstructive coronary artery 55 serum testosterone levels 55 hepatoma 55 bioavailable testosterone 55 IM progesterone 55 fractional shortening 55 potent suppressor 55 homocysteine concentrations 55 leukocyte counts 55 recombinant PSMA vaccine 55 axillary lymph nodes 55 -#.# ± [002] 55 Repliform R revenues 55 Cytotoxic T 55 endothelin antagonists 55 LV dysfunction 55 colorectal polyp 55 receiving Vectibix monotherapy 55 CYP#D# genotype 55 hematological relapse 54 salivary flow 54 onset diabetes mellitus 54 carotid artery intima media 54 diameter stenosis 54 postoperative bleeding 54 prostate cancer CaP 54 microgram kg 54 BUPHENYL R sodium phenylbutyrate 54 CDAI score 54 elevated LDH 54 Predict Response 54 MBq 54 thromboembolic events 54 hemodilution 54 serum sodium 54 chloride secretion 54 amoxicillin clavulanate 54 events MACE 54 irinotecan cisplatin 54 F FLT 54 ABC/3TC 54 anti HBs 54 + PH# 54 diuretic chlorthalidone 54 GnRH agonists 54 Upregulation 54 CCR5 delta# 54 anti JCV antibodies 54 tertile 54 elevated LDL cholesterol 54 bronchoalveolar lavage fluid 54 mineral density 54 Sustained virologic response 54 Bcl XL 54 serum PTH 54 abnormal hematopoietic cells 54 pathologic diagnosis 54 cortisol concentrations 54 inecalcitol 54 clinically evaluable patients 54 mucinous 54 mmol l 54 mU L 54 CHANGE WEEKLY CHANGE 54 PREZISTA ritonavir 54 multivariate Cox 54 p# activation 54 normal karyotype 54 Gastrointestinal Stromal Tumors 54 NIHSS score 54 ìg 54 stent stenosis 54 specific alkaline phosphatase 54 HER2 ErbB2 54 HT 1A 54 anemia leukopenia 54 genotypic resistance 54 del 5q 54 hypokalemia 54 SSc 54 lymphocyte count 54 epirubicin cyclophosphamide 54 hypogonadal 54 sensitivity specificity 54 concentration Cmax 54 inotropic 54 μg dL 54 hip resurfacing arthroplasty 54 TYMS 54 glycosylated hemoglobin levels 54 albumin excretion rate 54 immunoglobulin G 54 mm ³ 54 TOP2A 54 urinary albumin 54 tensin homolog 54 cerebrovascular events 54 colorectal neoplasia 54 CD# upregulation 54 mean ± SEM 54 response pCR 54 kaempferol 54 BYSTOLIC 54 GSTT1 54 mm Hg diastolic 54 CDKN2A 54 endometrial ovarian 54 pancreatic endocrine 54 PlGF 54 noncancerous prostate 54 impaired glucose metabolism 54 OGTT 54 progesterone receptor PR 54 hypervolemic 54 hepatic enzyme 54 cyclooxygenase COX 54 ps :# 54 anagrelide 54 Cyclin E 54 Annualized ROE 54 cellularity 54 bivalirudin monotherapy 54 TMPRSS2 ERG 54 vasodilatation 54 anovulatory 54 dose melphalan 54 mg QD 54 renal pelvis 54 liver enzymes ALT 54 #OHD 54 deCODE ProstateCancer TM 54 proton MR spectroscopy 54 orthotopic model 54 MIC# [001] 54 hematologic parameters 54 log# 54 Stomatitis 54 Metastases 54 promoter methylation 54 dose Iluvien 54 sirolimus stent 54 anthracycline induced 54 pegaptanib 54 rHuEPO